Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Moschini

Showing results (341-350 of 561) with videos related to

Pageof 57
Sort By:
Healthcare (Basel, Switzerland)|March 28, 2024
Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC)Valentina Da Prat, Lucia Aretano, Marco Moschini, et al.
Journal of Clinical Medicine|April 13, 2024
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder CancerRenate Pichler, Johannes Stäblein, Andrea Mari, et al.
Immunotherapy|June 3, 2021
Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysisEkaterina Laukhtina, Keiichiro Mori, Hadi Mostafaei, et al.
World Journal of Urology|June 2, 2021
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centersSimone Albisinni, Marco Moschini, Ettore Di Trapani, et al.
European Urology Oncology|January 6, 2024
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder CancerRoger Li, Luigi Nocera, Kyle M Rose, et al.
Urologic Oncology|August 3, 2020
Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on sizeKarl H Tully, Marco Moschini, Friedrich-Carl E von Rundstedt, et al.
Urologic Oncology|February 11, 2020
Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaborationFrancesco Soria, Andrea Giordano, David D'Andrea, et al.
Urologic Oncology|November 15, 2020
Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladderVictor M Schuettfort, David D Andrea, Fahad Quhal, et al.
BJU International|August 22, 2025
The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancerPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Urologic Oncology|February 14, 2026
Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathwayPietro Scilipoti, Giuseppe Rosiello, Alfonso Santangelo, et al.
Pageof 57

Showing results (341-350 of 561) with videos related to

Sort By:
Pageof 57
Healthcare (Basel, Switzerland)|March 28, 2024
Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC)Valentina Da Prat, Lucia Aretano, Marco Moschini, et al.
Journal of Clinical Medicine|April 13, 2024
Treating BCG-Induced Cystitis with Combined Chondroitin and Hyaluronic Acid Instillations in Bladder CancerRenate Pichler, Johannes Stäblein, Andrea Mari, et al.
Immunotherapy|June 3, 2021
Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysisEkaterina Laukhtina, Keiichiro Mori, Hadi Mostafaei, et al.
World Journal of Urology|June 2, 2021
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centersSimone Albisinni, Marco Moschini, Ettore Di Trapani, et al.
European Urology Oncology|January 6, 2024
Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder CancerRoger Li, Luigi Nocera, Kyle M Rose, et al.
Urologic Oncology|August 3, 2020
Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on sizeKarl H Tully, Marco Moschini, Friedrich-Carl E von Rundstedt, et al.
Urologic Oncology|February 11, 2020
Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaborationFrancesco Soria, Andrea Giordano, David D'Andrea, et al.
Urologic Oncology|November 15, 2020
Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladderVictor M Schuettfort, David D Andrea, Fahad Quhal, et al.
BJU International|August 22, 2025
The value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancerPaolo Zaurito, Pietro Scilipoti, Mattia Longoni, et al.
Urologic Oncology|February 14, 2026
Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathwayPietro Scilipoti, Giuseppe Rosiello, Alfonso Santangelo, et al.
Pageof 57